Clinical outcomes of FOLFIRINOX and gemcitabine–nab paclitaxel for metastatic pancreatic cancer in the real world setting

被引:0
作者
F. Franco
J. C. Camara
J. I. Martín-Valadés
A. López-Alfonso
D. Marrupe
D. Gutiérrez-Abad
B. Martínez-Amores
A. León
I. Juez
M. Pérez
A. Royuela
A. Ruiz-Casado
机构
[1] Hospital Universitario Puerta de Hierro,Department of Medical Oncology
[2] Fundación Hospital Alcorcón,Department of Medical Oncology
[3] Fundación Jiménez Díaz,Department of Medical Oncology
[4] Hospital Universitario Infanta Leonor,Department of Medical Oncology
[5] Hospital Universitario de Móstoles,Department of Medical Oncology
[6] Hospital Universitario de Fuenlabrada,Department of Medical Oncology
[7] Hospital Universitario Rey Juan Carlos,Department of Medical Oncology
[8] Hospital Universitario Puerta de Hierro,Department of Biostatistics
来源
Clinical and Translational Oncology | 2021年 / 23卷
关键词
Metastatic pancreatic cancer; Overall survival; Chemotherapy; Toxicity of treatment; Palliative care;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:812 / 819
页数:7
相关论文
共 101 条
[1]  
Minicozzi P(2018)Analysis of incidence, mortality and survival for pancreatic and biliary tract cancers across Europe, with assessment of influence of revised European age standardisation on estimates Cancer Epidemiol 55 52-60
[2]  
Cassetti T(2020)Cancer statistics, 2020 CA Cancer J Clin 70 7-30
[3]  
Vener C(2018)Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries Lancet 391 1023-1075
[4]  
Sant M(2017)Metastatic pancreatic cancer: American society of clinical oncology clinical practice guideline summary J Oncol Pract 13 261-264
[5]  
Siegel RL(2011)FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 1817-1825
[6]  
Miller KD(2013)Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial J Clin Oncol 31 23-29
[7]  
Jemal A(2013)Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine N Engl J Med 369 1691-1703
[8]  
Allemani C(2017)Patterns of chemotherapy use in a U.S.-based cohort of patients with metastatic pancreatic cancer Oncologist 22 925-933
[9]  
Matsuda T(2019)Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe Pancreatology 19 97-104
[10]  
Di Carlo V(2020)Some unanswered questions about older adults with metastatic pancreatic cancer J Geriatr Oncol 11 1032-1033